-
TAILOR RT: A RANDOMIZED TRIAL OF REGIONAL RADIOTHERAPY IN BIOMARKER LOW RISK NODE POSITIVE BREAST CANCER
The purpose of this study is to determine whether there is any benefit of regional radiotherapy and to compare good and bad effects of not ... -
RANDOMIZED PLACEBO-CONTROLLED SINGLE BLINDED MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF YONI.FIT IN WOMEN WITH STRESS URINARY INCONTINENCE (SUI)
This study will look at how safe and how well the investigational device, Yo¯ni.Fit® device works in improving the symptoms of stress urinary ... -
Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly
Fetal complete (i.e., third degree) atrioventricular block (AVB), identified in the 2nd trimester of pregnancy in an otherwise normally developing heart, is almost universally ... -
The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD) A Double-Blinded Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib
The purpose of the study is to determine if the invasive disease-free survival (iDFS) with T-DM1 and tucatinib is superior to the iDFS in the ... -
Melanoma Margins Trial (MelMarT): A Phase III Multi-Centre Multi-National Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma.
You can participate in this study if you are diagnosed with skin melanoma stage 2. This study will determine whether there is a difference in ... -
Randomized multicenter open-label phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FRa-positive recurrent platinum-sensitive ovarian cancer
This study is designed for patients diagnosed with FRa-positive recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers after second line platinum-based chemotherapy plus ...
-
A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA
This is a study to test a drug called selinexor for patients with EC (endometrial carcinoma). The drug will be given to patients who have ...